Molecular basis of atrial fibrillation pathophysiology and therapy: a translational perspective

S Nattel, J Heijman, L Zhou, D Dobrev - Circulation research, 2020 - Am Heart Assoc
Circulation research, 2020Am Heart Assoc
Atrial fibrillation (AF) is a highly prevalent arrhythmia, with substantial associated morbidity
and mortality. There have been significant management advances over the past 2 decades,
but the burden of the disease continues to increase and there is certainly plenty of room for
improvement in treatment options. A potential key to therapeutic innovation is a better
understanding of underlying fundamental mechanisms. This article reviews recent advances
in understanding the molecular basis for AF, with a particular emphasis on relating these …
Atrial fibrillation (AF) is a highly prevalent arrhythmia, with substantial associated morbidity and mortality. There have been significant management advances over the past 2 decades, but the burden of the disease continues to increase and there is certainly plenty of room for improvement in treatment options. A potential key to therapeutic innovation is a better understanding of underlying fundamental mechanisms. This article reviews recent advances in understanding the molecular basis for AF, with a particular emphasis on relating these new insights to opportunities for clinical translation. We first review the evidence relating basic electrophysiological mechanisms to the characteristics of clinical AF. We then discuss the molecular control of factors leading to some of the principal determinants, including abnormalities in impulse conduction (such as tissue fibrosis and other extra-cardiomyocyte alterations, connexin dysregulation and Na+-channel dysfunction), electrical refractoriness, and impulse generation. We then consider the molecular drivers of AF progression, including a range of Ca2+-dependent intracellular processes, microRNA changes, and inflammatory signaling. The concept of key interactome-related nodal points is then evaluated, dealing with systems like those associated with CaMKII (Ca2+/calmodulin-dependent protein kinase-II), NLRP3 (NACHT, LRR, and PYD domains-containing protein-3), and transcription-factors like TBX5 and PitX2c. We conclude with a critical discussion of therapeutic implications, knowledge gaps and future directions, dealing with such aspects as drug repurposing, biologicals, multispecific drugs, the targeting of cardiomyocyte inflammatory signaling and potential considerations in intervening at the level of interactomes and gene-regulation. The area of molecular intervention for AF management presents exciting new opportunities, along with substantial challenges.
Am Heart Assoc